Treatment
Cisplatin/ Carboplatin clinical trials
We’re tracking 168 recruiting studies that include Cisplatin/ Carboplatin, each written for real people, not researchers, below.
Recruiting studies
- NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Bullhead City, ArizonaAges 18 years+ - NCT07601737RecruitingPhase 2
Nimotuzumab with immunotherapy and chemotherapy for head and neck cancer
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
ShanghaiAges 18–75 - NCT06512051RecruitingPhase 1/Phase 2
Study of SHR-A2102 and Adebrelimab for advanced lung cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–70 - NCT06536868RecruitingPhase 2
Tislelizumab with chemo and radiation for extensive-stage small cell lung cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
Jincheng, ShanxiAges 18–80 - NCT06829459RecruitingPhase 3
New drug combo vs chemo for resistant lung cancer
This trial tests a combination of two targeted drugs (Glumetinib and Osimertinib) against standard chemotherapy for people with non-small cell lung cancer that has stopped responding to initial targeted therapy. It may be an option if your tumor has a specific genetic change called MET amplification or overexpression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT06859775RecruitingPhase 1/Phase 2
SHR-A1811 combination for recurrent or metastatic cervical cancer
This study tests whether a new drug combination called SHR-A1811 can help people with cervical cancer that has come back or spread. It aims to find a better treatment option for those who have limited choices.
Beijing, Beijing MunicipalityAges 18–75 - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Los Angeles, CaliforniaAges 18 years+ - NCT07008716RecruitingPhase 3
Omitting CTV for primary tumor in limited-stage small cell lung cancer
This trial tests whether treating the main tumor alone, without the nearby lymph nodes, can work as well in limited-stage small cell lung cancer after initial chemotherapy. You may qualify if you have not had disease progression after 2-4 cycles of standard chemo and meet other health criteria.
Guangzhou, GuangdongAges 18–75 - NCT07106762RecruitingPhase 2/Phase 3
Study of new targeted drug vs chemo for bladder cancer
This trial tests a new drug called Izalontamab Brengitecan (a targeted therapy that delivers chemo straight to cancer cells) against standard platinum chemotherapy for people whose bladder cancer worsened after immunotherapy. It may be an option if you are fit for chemo but haven't had platinum chemo recently.
Gilbert, ArizonaAges 18 years+ - NCT07279935RecruitingPhase 4
Testing osimertinib with chemo for lung cancer that returned
This trial is for people with a specific type of lung cancer (EGFR-mutated non-small cell) that has come back in another part of the body after finishing treatment with osimertinib after surgery. It tests whether giving osimertinib again plus chemotherapy can help control the cancer.
BeijingAges 18 years+ - NCT01704716RecruitingPhase 3
Study for high-risk neuroblastoma in children and teens
This Phase 3 trial tests treatments for children and teens with high-risk neuroblastoma, aiming to improve outcomes by using biology-based risk information. It also requires limited prior chemotherapy and specific timing after diagnosis.
AdelaideAges 1 month–21 years - NCT01887340RecruitingPhase 2
PET-guided treatment for seminoma based on scan response
This Phase 2 study tests a treatment plan guided by a PET scan over time in people with seminoma after testicle removal. It aims to tailor therapy based on how cancer shows up on the scan, potentially helping avoid unnecessary treatment intensity.
Villejuif, Val de MarneAges 18 years+ - NCT06281964Enrolling by invitationPhase 3
New pill for EGFR Exon 20 lung cancer
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
Guangzhou, GuangzhouAges 18 years+ - NCT05582265RecruitingPhase 3
Study immune drug plus chemo before surgery versus surgery first
This Phase 3 trial compares two treatment plans for stage III/IVA head and neck squamous cell cancer (HNSCC). One plan uses an immune drug with chemotherapy before surgery; the other goes straight to surgery first, to see which approach works better.
Guanzhou, GuangdongAges 18–80 - NCT06323369RecruitingPhase 2
Tislelizumab plus chemo before surgery vs surgery alone for head and neck cancer
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
Guangzhou, YuexiuAges 18–75 - NCT07061977RecruitingPhase 3
New cancer drug combo for advanced cervical cancer
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
Birmingham, AlabamaAges 18 years+ - NCT07281417RecruitingPhase 2
Testing adding cemiplimab to chemo before surgery for sinus cancer
This trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy before surgery helps treat sinonasal squamous cell carcinoma. The goal is to see if this combination reduces tumors more effectively than chemotherapy alone.
Irvine, CaliforniaAges 18 years+ - NCT06312137RecruitingPhase 3
Pembrolizumab with or without another drug for lung cancer after surgery
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
Little Rock, ArkansasAges 18 years+ - NCT03547973RecruitingPhase 2
Study of sacituzumab govitecan for advanced or non-removable bladder cancer
This trial tests sacituzumab govitecan, an anti-cancer drug, for people with urothelial (bladder/urinary tract) cancer that has spread or can’t be removed with surgery. It’s designed for tumors that have been treated already in specific ways, to see if the medicine can shrink or control the cancer.
Tucson, ArizonaAges 18 years+ - NCT06489808RecruitingPhase 2
Linperlisib plus chemoimmunotherapy for relapsed large B-cell lymphoma
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07276399RecruitingPhase 3
Study of amivantamab plus standard care for head and neck cancer
This trial tests whether adding the drug amivantamab to usual treatments helps people with advanced head and neck cancer that has come back or spread. It compares the combination to standard care alone.
Chandler, ArizonaAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT04585490RecruitingPhase 3
Testing a personalized add-on treatment after stage III lung cancer
This phase 3 trial tests whether tailoring the next (add-on) treatments can improve outcomes after standard chemoradiation and immunotherapy for stage III, unresectable (not operable) non-small cell lung cancer. It specifically looks at giving durvalumab plus an additional drug (tremelimumab) and possibly other consolidation chemotherapy based on a personalized plan.
Stanford, CaliforniaAges 18 years+
Common questions
- Are there clinical trials studying Cisplatin/ Carboplatin?
- Yes. Clin2 currently lists 168 recruiting studies that include Cisplatin/ Carboplatin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cisplatin/ Carboplatin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cisplatin/ Carboplatin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cisplatin/ Carboplatin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.